key: cord-0848369-pdglftd0
authors: Mor, Saban; Vicki, Myers; Rachel, Wilf-Miron
title: Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case
date: 2021-11-17
journal: Prev Med
DOI: 10.1016/j.ypmed.2021.106890
sha: 3b834423d1557490b5c0b94238178ec7f21b0088
doc_id: 848369
cord_uid: pdglftd0

We present epidemiological data to examine trends in COVID-19 incidence, morbidity and mortality in Israel as well as changes in vaccine effectiveness, and discuss the impact of the delta variant and the third, “booster”, vaccine. A retrospective-archive study was conducted from February 27th 2020 to October 16th, 2021. Data were obtained from the Israeli Ministry of Health's open COVID 19 database, including PCR-confirmed cases, number hospitalized - including severe cases, death rate, all by age and vaccination status, case fatality rate and changing effectiveness of the vaccine. After three COVID waves, confirmed cases rose from under 30 new daily cases in mid-June to a high of 11,000 in early September 2021. Severe hospitalized cases and death rates were lower than in previous waves and largely restricted to those not fully vaccinated. In the first three months of the vaccination campaign, non-vaccinated population demonstrated much higher morbidity rates. Four months after vaccination began, this gap was attenuated, with low rates of infection and hospitalization in all groups. The gap was regained following uptake of the third vaccine. Data from the fourth wave show reduced hospitalizations and mortality compared to previous waves and suggest that this may be related to high vaccine coverage. These trends suggest that countries with high vaccination might adopt a more permissive approach towards COVID even in the face of new variants.

Twelve months after the first COVID-19 cases were reported in Wuhan, China 1 the first COVID vaccine was authorized by the US FDA for emergency use and many countries initiated national vaccine drives. 2 In Israel, the Pfizer mRNA COVID-19 vaccine BNT162b2 was available from December 2020 as the only vaccine brand, and was offered first to healthcare workers, the elderly (aged 60+) and at-risk populations with underlying disease. On February 20, 2021 vaccination was opened up to the entire adult (16+) population and in June 2021, it was offered for the first time to 12-15 year olds. Individuals recovered from COVID infection were given a single vaccine dose. In the first three months of the vaccination campaign, Israel had the largest share of the population having received at least one vaccine dose. 3 As of 6 th July, 66% of the Israeli population (total population: 9 .354 million people) 4 has been fully vaccinated and more than 90% of those aged This study presents epidemiological data to examine trends in COVID-19 incidence, morbidity and mortality in Israel since the beginning of the vaccination campaign, and discusses the impact of the new delta variant. We present here data on new confirmed COVID-19 cases (positive PCR test in the last 24 hours), , severe disease (including critically ill patients) 7 among those hospitalized with COVID-19, number of deaths from COVID-19 and reproduction number (R), calculated as the mean number of infections resulting from a single case, and reported with an average 10 day lag. 8 The latter index tracks trends of viral spread at the national level, in addition to daily confirmed cases.

In addition, we present weekly number and rate of confirmed cases, hospitalizations, and deaths by vaccination status (vaccinated with 1 dose, 2 dose2, 3 doses and nonvaccinated). Non-vaccinated were defined as those who had not received any vaccine (or were less than 1 week after their first dose). Fully vaccinated were defined as those with two doses, and at least a week following the second dose, up to September 29 2021, and after this date those with three doses (and at least a week following the J o u r n a l P r e -p r o o f Journal Pre-proof last dose). Partially vaccinated were defined as those with one vaccine (up to late September 2021) or two doses from September 29, 2021 and on. These data were collated and presented in graph form, detailing morbidity between 20/12/20-16/10/21.in people who had received the first, second and third vaccine doses.

Number of deaths by age and vaccination status is an approximation since periods with less than 5 deaths were noted in the database as <5 which we substituted for n=3 which could be an overestimation.

Case fatality rate (CFR) was calculated from MOH data as the number of deaths divided by the number of confirmed cases. 9 Rates of infection and severe disease were calculated from MOH data and presented per 100,000 in vaccinated and unvaccinated populations, with significant difference between rates compared using chi-squared test.

To date there were four waves of COVID-19 in Israel, the first in March-April 2020, the second beginning at the end of June 2020 until October 2020, and the third, with The highest number and rate of deaths in all age groups occurred in non-vaccinated people (Fig 4c) . Mortality related to COVID throughout the pandemic period was very low in children and young people (Fig 4c&4d) . Furthermore, case fatality rate Detailed monthly data for the study period is presented in Table 1 , which demonstrates rates of severe disease that were 6 times higher for non-vaccinated, compared with vaccinated individuals, in February 2021 (13.09 and 2.18 cases per 100,000 vaccinated and non-vaccinated population, respectively). In May 2021 the gap narrowed, and in June rates decreased in both groups to almost equalize (0.81 and 0.14 per 100,000 population of vaccinated and non-vaccinated, respectively). In August this gap increased again to be 5 times higher in the unvaccinated population.

In late September the gap further increased, with rates among vaccinated being 6 times lower compared with non-vaccinated or partially vaccinated (2.69 and 17.54 per 100,000 population, respectively) ( Table 1 ). Rate of infection followed the same pattern, being much higher in the unvaccinated population, with the gap reducing in June-July, and increasing again from August to October.

Israel has experienced four waves of the COVID-19 pandemic, with multiple J o u r n a l P r e -p r o o f Journal Pre-proof lockdowns, a death toll of over 8000, and significant economic ramifications.

Having almost eradicated COVID in April 2021, cases began to rise in June, reaching the peak of a fourth wave in September 2021. However, while an increase in confirmed cases and a rising R rate was reported, the rate of severe hospitalized cases and deaths was lower than in previous waves. 13 compared to the alpha strain, but its analysis revealed that two doses of vaccine gave a high degree of protection against hospital admission, estimated to be more than 90%. 6 The UK has also reached a high proportion of vaccinations per population compared to other countries. 3 While the UK has now reached higher rates of vaccination, compared with Israel, this is because it has a year olds. This might partially explain why the recent increase in new infections has not been matched by an increase in severe disease or mortality, since COVID is known to cause greatest morbidity in older age-groups. 16 For the vast majority of children, COVID presents a minimal threat. Furthermore, the small risk in children of severe disease has become even smaller in recent months, with the rate of children J o u r n a l P r e -p r o o f Journal Pre-proof under 10 being ventilated due to COVID being 0.008% since the start of the pandemic, reducing to 0.004% in the last 3 months; and the case fatality rate reducing from 0.002% to 0.0008%. 17 This may be due to better recognition of the disease and better treatment options. Despite the lower severity of the acute-phase COVID among children, 18 questions remain regarding the prevalence of long COVID in children, however according to some reports reported symptoms do not seem to exceed the prevalence of symptoms such as headache or cough among the pediatric population. 19 The disappearing gap in infections and severe disease between vaccinated and non-vaccinated populations, three months after the national vaccine drive began, suggested that the high rate of population vaccination succeeded in giving protection to non-vaccinated people, and overall reduction of the number of infections. However once cases began to rise again with the fourth wave, the gap opened up again with a higher rate of severe cases and deaths among those unvaccinated or partially vaccinated population. Following the sharp reduction in cases that marked the end of the third pandemic wave, most restrictions and public health measures were removed in Israel in April/May 2021 once cases dropped, including revoking the need for masks in indoor spaces. However several restrictions, including the "Green pass" incentives for those vaccinated, were reintroduced in September 2021 given the rising R and number of confirmed cases. In an attempt to reduce quarantine of whole classes in October 2021, the 'green classroom' system was trialed, whereby instead of sending a whole class into quarantine following one confirmed cases, children complete daily tests but continue to go to school. COVID risk should also be placed in the context of other viral diseases. While prior to the vaccination campaign, CFR for COVID was highr (0.77% in Israel, 2.2% reported worldwide), 20 older population was at significant risk, and there was genuine concern about overwhelming the healthcare system. In the current circumstances of highly vaccinated risk groups, and a lower case fatality rate, approaches towards COVID might take a different perspective. Vaccines, including the booster, should continue to be made widely available, and trends must continue to be monitored, so that informed decisions can be made about the safe and timely lifting of restrictions.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

J o u r n a l P r e -p r o o f 

The epidemiological characteristics of 2019 novel coronavirus diseases (COVID-19

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine -United States

COVID-19) Vaccinations -Statistics and Research -Our World in Data. 4. Population of Israel on the Eve of 2021

Covid-19: Cases of delta variant rise by 79%, but rate of growth slows

A minimal common outcome measure set for COVID-19 clinical research

The estimation of the basic reproduction number for infectious diseases

Early estimation of the case fatality rate of COVID-19 in 04/he/NEWS_Corona_vaccine-eficacy

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Risk assessment for SARS-CoV-2 variant: Delta (VOC-21APR-02, B.1.617.2) Public Health England Indicator RAG* Confidence Assessment and rationale

Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months

United States at a glance. Center for Disease Control

The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression

Israel Ministry of Health COVID-19 dashboard. 2021. datadashboardba.health.gov.il/COVID-19/general

More research is needed on the long-term effects of COVID-19 on children and adolescents

Vaccinating children to prevent long covid? More caution is needed in interpreting current epidemiological data

COVID-19 Map -Johns Hopkins Coronavirus Resource Center. influenza A(H1N1pdm09): a systematic review

Pfizer says it is developing a Covid booster shot to target the highly transmissible delta variant

Protection of BNT162b2 vaccine booster against covid-19 in Israel

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, communitybased, nested, case-control study